[Single nucleotide polymorphism and novel drug discovery].

Area of Science:

• Pharmacogenomics
• Molecular Biology
• Drug Development

Background:

• Genetic polymorphisms significantly influence drug response and disease susceptibility.
• Understanding these variations is crucial for personalized medicine.
• Current drug development lacks comprehensive integration of genetic factors.

Purpose of the Study:

• To highlight the role of genetic polymorphisms in identifying therapeutic targets.
• To emphasize the necessity of gene examination in clinical trials for patient stratification.
• To underscore the impact of genetic variations on drug pharmacokinetics, metabolism, efficacy, and toxicity.

Main Methods:

• Review of existing literature on genetic polymorphisms and drug response.
• Analysis of the implications of genetic variations in drug development pipelines.
• Case study examples illustrating the impact of pharmacogenomics in clinical trials.

Main Results:

• Genetic polymorphisms can serve as biomarkers for predicting drug efficacy and toxicity.
• Gene examination allows for the classification of patients into responders and non-responders.
• Pharmacokinetic and metabolic profiles are demonstrably altered by specific genetic variations.

Conclusions:

• Genetic polymorphism research is essential for discovering novel therapeutic targets.
• Integrating gene examination into clinical trials enhances drug development efficiency and patient safety.
• Pharmacogenomic insights are critical for optimizing drug selection and minimizing adverse events.